Journal article

Incorporation of triphenylphosphonium functionality improves the inhibitory properties of phenothiazine derivatives in Mycobacterium tuberculosis.

Elyse A Dunn, Marina Roxburgh, Lesley Larsen, Robin AJ Smith, Alexander D McLellan, Adam Heikal, Michael P Murphy, Gregory M Cook

Bioorganic & Medicinal Chemistry | Published : 2014


Tuberculosis (TB) is a difficult to treat disease caused by the bacterium Mycobacterium tuberculosis. The need for improved therapies is required to kill different M. tuberculosis populations present during infection and to kill drug resistant strains. Protein complexes associated with energy generation, required for the survival of all M. tuberculosis populations, have shown promise as targets for novel therapies (e.g., phenothiazines that target type II NADH dehydrogenase (NDH-2) in the electron transport chain). However, the low efficacy of these compounds and their off-target effects has made the development of phenothiazines as a therapeutic agent for TB limited. This study reports that..

View full abstract

University of Melbourne Researchers